Biotech
Aug. 28, 2013
"Moribund" VC market tests biotechs
Investors have jumped into biotech IPOs with unprecedented zeal this year, but that enthusiasm has yet to spread to the private equity market for life science startups.
Daily Journal Staff Writer
Investors have jumped into biotech IPOs with unprecedented zeal this year, but that enthusiasm has yet to spread to the private equity market for life sciences startups. Rather, it's been a tale of two capital markets - a "frothy" public one and "moribund" private one, as O'Melveny & Myers LLP's life sciences partner Sam Zucker put it - and venture funding is still nowhere...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In